Drug Profile
Tusamitamab ravtansine - Sanofi
Alternative Names: IBI-126; Maytansin-loaded anti-CEACAM5 mAb; SAR '701; SAR-408701Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer Erasmus MC; Sanofi
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 28 Feb 2024 Sanofi withdrew a phase II trial in Breast cancer, Non small cell lung cancer and Gastric cancer (Metastatic disease, Second-line therapy or greater) in Netherlands (IV) prior to enrollment due to the decision to discontinue the candidate's global clinical development (EudraCT2022-003451-34; NCT05703555)
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 21 Dec 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in Japan (IV)